1508-76-5 Usage
Description
Procyclidine hydrochloride, also known as α-cyclohexyl-α-phenyl-1-pyrrolidinepropanol hydrochloride (Kemadrin), is an anticholinergic drug that was introduced in 1956. It is effective as a peripheral anticholinergic and has been used for peripheral effects similar to its methochloride (i.e., tricyclamol chloride). However, its clinical usefulness lies in its ability to relieve voluntary muscle spasticity through its central action, making it a successful treatment for Parkinson syndrome.
Uses
Used in Parkinson's Disease Treatment:
Procyclidine hydrochloride is used as an anticholinergic drug for the treatment of Parkinson's disease. It helps in reducing muscle rigidity in postencephalitic, arteriosclerotic, and idiopathic types of the disease. Its effect on tremor is not always predictable and may require supplementation with other similar drugs.
Used in Drug-Induced Parkinsonism Treatment:
Procyclidine hydrochloride is also used to treat patients suffering from drug-induced parkinsonism, which is a side effect of certain medications.
Used in Akathisia Treatment:
The drug is utilized to alleviate akathisia, a disorder characterized by a feeling of inner restlessness and a compelling need to move.
Used in Acute Dystonia Treatment:
Procyclidine hydrochloride is employed to treat acute dystonia, a movement disorder that causes involuntary muscle contractions, which can lead to abnormal postures or repetitive movements.
Brand Name:
Kemadrin (Monarch) is the brand name under which Procyclidine hydrochloride is marketed.
Biochem/physiol Actions
Procyclidine is a synthetic anti-cholinergic agent and atropine-like antispasmodic. It exhibits therapeutic effects against Parkinson′s disease and schizophrenia. Procyclidine acts as a muscarinic receptor antagonist. It also affects N-methyl-D-aspartate (NMDA) glutamine and nicotinic acetylcholine receptors to a lower extent.
Clinical Use
Control of extrapyramidal symptoms
Acute dystonias
Drug interactions
Potentially hazardous interactions with other drugs
None known
Metabolism
When given orally about one fifth of the dose is known
to be metabolised in the liver, principally by cytochrome
P450 and then conjugated with glucuronic acid.
Metabolites have been found in the urine.
Check Digit Verification of cas no
The CAS Registry Mumber 1508-76-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,5,0 and 8 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1508-76:
(6*1)+(5*5)+(4*0)+(3*8)+(2*7)+(1*6)=75
75 % 10 = 5
So 1508-76-5 is a valid CAS Registry Number.
InChI:InChI=1/C19H29NO.ClH/c21-19(17-9-3-1-4-10-17,18-11-5-2-6-12-18)13-16-20-14-7-8-15-20;/h1,3-4,9-10,18,21H,2,5-8,11-16H2;1H
1508-76-5Relevant articles and documents
Aryl-cycloalkyl-alkanolamines for treatment of neurotoxic injury
-
, (2008/06/13)
Compounds, compositions and methods of treatment are described to control brain damage associated with anoxia or ischemia which typically follows such conditions as stroke, cardiac arrest or perinatal asphyxia. The treatment includes administration of an aryl-cycloalkyl-alkanolamine compound as an antagonist to inhibit excitotoxic actions at major neuronal excitatory amino acid receptor sites.
